Papers
1
Total Citations
2
H-Index
1
About
Dongbo Xu is a prominent urologic oncologist whose research focuses on improving surgical outcomes and prognostic accuracy in bladder cancer treatment. His work centers on the oncological implications of tumor location and extent during radical cystectomy, particularly in the context of robot-assisted surgery. In his highly cited 2024 study, Xu demonstrated that tumor involvement of the trigone and urethra at the time of robot-assisted radical cystectomy is significantly associated with adverse oncological outcomes, including higher rates of recurrence and reduced survival. This finding has critical implications for surgical planning and patient counseling, emphasizing the need for careful preoperative assessment of tumor topography. Xu’s research contributes to the growing body of evidence refining patient selection for nerve-sparing and urethra-sparing approaches, ultimately aiming to balance oncologic control with quality of life. His work is widely recognized for its clinical relevance, with his most cited paper accumulating 2 citations in a short period, reflecting its immediate impact on urologic practice. Xu continues to advance the field through collaborative studies on minimally invasive techniques and long-term outcomes in bladder cancer management.
Research Focus
Key Achievements
Top Papers
- 1